Invivyd, Inc. (IVVD) News
Follow Invivyd, Inc. (IVVD) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 14 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Invivyd LIBERTY Phase 3: VYD2311 Shows Superior Safety vs mRNA Vaccine; BLA Plans
Invivyd announced LIBERTY Phase 3 topline results showing VYD2311 safety and tolerability clinically and statistically superior to an mRNA COVID-19 vaccine and plans regulatory submissions for VYD2311.Key Highlights:Orig
REGULATION | Sep 29, 2026, 11:33 AM UTC
L
Invivyd, Inc. (IVVD) Posts Positive Phase 3 LIBERTY Data, Plans Accelerated BLA
Invivyd reported positive topline Phase 3 LIBERTY data showing VYD2311 safety/tolerability favorable vs an mRNA COVID-19 vaccine and no immunologic interference, and said it intends to submit a BLA under the FDA Accelera
REGULATION | Sep 29, 2026, 11:09 AM UTC
M
Invivyd announces positive LIBERTY Phase 3 topline results for VYD2311
Invivyd (IVVD) reported positive topline results from its LIBERTY Phase 3 study for VYD2311, stating safety and tolerability and that they are superior to mRNA-based COVID-19 vaccines. The company also announced plans fo
EQUITY | Sep 29, 2026, 11:07 AM UTC
L
IVVD: Next-gen monoclonal antibody aims to redefine COVID-19 prevention with scalable, flexible dosing
The company is advancing a next-generation monoclonal antibody for COVID-19 prevention, with pivotal trial data expected soon and regulatory strategies under consideration. Commercial efforts focus on scalable, consumer-
NEWS | Sep 14, 2026, 10:12 PM UTC
L
IVVD: Phase III data for a scalable COVID-19 monoclonal antibody is imminent, with broad market ambitions
The company is advancing a next-generation monoclonal antibody for COVID-19, with phase III data imminent and regulatory strategies under consideration. Plans include transitioning to a more scalable, vaccine-like produc
NEWS | Sep 14, 2026, 09:42 PM UTC
L
IVVD - Invivyd to Participate in Upcoming September Investor Conferences
IVVD - Invivyd to Participate in Upcoming September Investor Conferences
EQUITY | Sep 08, 2026, 11:01 AM UTC
L
Invivyd grants inducement options under Nasdaq Rule 5635(c)(4)
Invivyd says it granted options on Sept. 1, 2026 to six newly hired non-executive employees for an aggregate 255,000 shares of common stock as material inducements under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 03, 2026, 11:08 AM UTC
L
Invivyd reports inducement grants under Nasdaq Rule 5635(c)(4)
Invivyd reported inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 03, 2026, 11:01 AM UTC
L
Invivyd appoints Marc Elia as CEO, adds Sheffield to board
Invivyd appointed Marc Elia as chief executive officer and added Ian Sheffield to its board, both effective Aug. 30, 2026.
REGULATION | Sep 01, 2026, 11:14 AM UTC
L
Invivyd appoints Marc Elia as CEO, retaining him as chairman
Invivyd said it appointed Marc Elia, current board chairman, as Chief Executive Officer. He will serve as chairman and CEO going forward.
EQUITY | Sep 01, 2026, 11:07 AM UTC
L
Invivyd appoints Marc W. Elia as CEO
Invivyd appoints Chairman Marc W. Elia as chief executive officer.
EQUITY | Sep 01, 2026, 11:01 AM UTC
L
Invivyd price target maintained at $10.00 by Cantor Fitzgerald
Cantor Fitzgerald maintained its Invivyd price target at $10.00 per share, per TradingView News.
EQUITY | Aug 27, 2026, 11:24 AM UTC
L
Invivyd reports Q2 2026 financial results and business highlights
Invivyd (IVVD) reports its second quarter 2026 financial results along with recent business highlights, as provided by TradeXchange Newsdesk.
EARNINGS | Aug 13, 2026, 08:08 PM UTC
L
The FDA Sent Invivyd An Advance Termination Notice For Pemgarda (Pemivibart) Emergency Use Authorization Following US Department Of Health A
U.S. Department of Health and Human Services (HHS) announced advanced Notice of Termination of the COVID-19 EUA declaration, effective June 29, 2027 Consequently, Invivyd received from the U.S. Food and Drug Administrati
REGULATION | Jul 06, 2026, 11:11 AM UTC